David Kirn - Feb 1, 2022 Form 4 Insider Report for 4D Molecular Therapeutics Inc. (FDMT)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ August J. Moretti, Attorney-in-Fact for David Kirn
Stock symbol
FDMT
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 04:40 PM
Next filing
Dec 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FDMT Common Stock 2M Feb 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Award $0 +150K $0.00 150K Feb 1, 2022 Common Stock 150K $15.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.

Remarks:

Chief Executive Officer